Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
There are no FDA‑ or EMA‑approved Angiotensin II receptor blockers (ARBs) that are indicated specifically for treating Type 2 diabetes (T2D) itself as a primary glucose‑lowering therapy. However, several AT1‑receptor blockers (ARBs) are approved for use in patients with T2D who have hypertension and/or diabetic kidney disease, mainly to protect the kidneys and reduce cardiovascular risk, not to treat hyperglycemia per se.
…